Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development

by Ysios Capital

Proceeds to support clinical development of lead first-in-class program ONA-255 in breast cancer, toward clinical proof of concept, and advance ONA-389 in colorectal cancer

Read more

Ysios Capital participates in $135 million Series B round of Adcendo ApS to fund the development of first-in-class ADCs for the treatment of certain cancers

by Ysios Capital

Adcendo, a biotech company focused on the development of first-in-class ADCs for the treatment of cancers with a high unmet medical need, today announced the successful closing of an oversubscribed $1...

Read more

Un biomarcador ayuda a seleccionar a las pacientes que más responden a patritumab deruxtecán en cáncer de mama

by Fundació Clínic per a la Recerca Biomèdica

Un estudio promovido por SOLTI y publicado en Nature Communications describe la biología del tumor asociada a la actividad del fármaco patritumab deruxtecán, un anticuerpo conjugado a quimioterapia...

Read more
Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Rethinking Alzheimer’s clinical trials...

by Fundació Clínic per a la Recerca Biomèdica

A paper published in Alzheimer’s & Dementia: The Journal of the Alzh...

Photos Stream